<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A4252EE9-98DF-4F4C-8536-F9A3F89C5417"><gtr:id>A4252EE9-98DF-4F4C-8536-F9A3F89C5417</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>May</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ008176%2F1"><gtr:id>911BBFC2-A764-4475-B122-2D4D22B1DAD6</gtr:id><gtr:title>DEALING WITH THERAPY-RESISTANT CRYPTOCOCCOSIS BY TARGETING INTRACELLULAR PATHOGENS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J008176/1</gtr:grantReference><gtr:abstractText>Cryptococcosis is a life-threatening fungal disease that kills more than 600 000 patients per annum worldwide. The majority of these individuals are newly diagnosed HIV-positive patients in the developing world, for whom the prognosis is relatively good, PROVIDED that they survive the cryptococcal infection. In addition, there is a globally increasing incidence of cryptococcal infection in otherwise healthy people, which appears to be due to the occurrence of localized, hypervirulent populations of the fungus. Thus understanding more about the biology of this pathogen, and developing ways to improve treatment of it, is critical.
One major problem is that the 'best practice' antifungal treatment available still fails in more than 10% of patients. One reason for this is that, during an infection, some cryptococcal cells 'hide' within white blood cells of the patient. These intracellular fungi are not exposed to high enough levels of antifungal drugs and can thus act as 'reservoirs' of disease. 

To try and address this problem, our proposal aims to identify drugs that can be used to stimulate the expulsion of intracellular cryptococci from white blood cells, thus exposing them to lethal levels of antifungal drugs in the circulation. Our group has recently discovered just such an expulsion process, which we call vomocytosis, and shown that it can be stimulated by applying different agents, such as the anti-malarial drug chloroquine. 

In order to move this finding into the clinic, we need to follow two lines of investigation. Firstly, we need to understand the molecular events that happen within infected white blood cells and lead to fungal expulsion. Such information is essential if we are to devise methods of manipulating that process without causing unwanted 'collateral damage' (for instance, dramatically impairing the body's ability to tackle other pathogens that may be infecting at the same time as Cryptococcus). Secondly, we plan to undertake a high-throughput screen to identify new, more effective, compounds that stimulate cryptococcal expulsion. Importantly, we will take a 'new tricks for old drugs' approach, focusing our search on the list of (&amp;gt;1000) compounds that have already been approved by the Food and Drug Administration. These drugs therefore meet minimum safety standards and have already been used to treat other disease conditions. Therefore compounds that we identify can be moved into clinical practice more rapidly and more cheaply than totally new molecules.

At the end of the project, we will thus have provided both important new information about a fatal human disease and revealed a set of compounds that might, in the near future, be utilized to help treat that disease.</gtr:abstractText><gtr:technicalSummary>The etiological agents of cryptococcosis, Cryptococcus neoformans and C. gattii , are both facultative intracellular pathogens that can survive and proliferate within macrophages. Intracellular yeast represent a reservoir of disease that is difficult to eradicate with current antifungal regimes. We have recently identified a novel expulsion process, termed vomocytosis, by which intracellular cryptococci exit macrophages. In addition, we have shown that vomocytosis can be enhanced by the application of specific cytokine subsets, gaseous stimuli or chemical agents. 

Here we propose a programme of work to both investigate the intracellular behaviour of cryptococci and identify agents that manipulate this behaviour. Specifically, we will:
a) identify the molecular steps that lead to cryptococcal expulsion 
b) determine how differing execution of these steps leads to inter-strain variation in these infectious species
c) identify compounds that induce vomocytosis, and
d) reveal the mode of action of such compounds. 

In following this line of investigation, our intention is to develop a new therapeutic strategy to accelerate fungal clearance in patients. This strategy is based around combining existing antifungal regimes with new compounds, identified from our screen, which will induce the expulsion of intracellular cryptococci, rendering them susceptible to the antifungal agents. Our approach, focusing on a drug-redeployment screen within current FDA-approved compounds, is likely to identify agents that are safe in patients and can be rapidly deployed into clinical settings. In addition, we are mindful of the fact that analogous pathogen expulsion processes have recently been identified in a range of infectious organisms. Thus findings we make as part of this proposal are likely to have far-reaching consequences both in terms of fundamental microbiology and translational approaches for dealing with intracellular infections.</gtr:technicalSummary><gtr:potentialImpactText>The major beneficiaries of our research will ultimately be cryptococcosis patients, particularly those for whom best-practice antifungal treatment does not lead to a rapid rate of fungal clearance and who are thus at the highest risk of death. As with any novel therapeutic approach, it will take time for our findings to be adopted in clinical practice. However, by focusing our drug-screening approach on existing FDA-approved compounds, we aim to identify lead molecules that can be rapidly and cheaply 'rolled out'; certainly on a much shorter timescale than the 17 years that MRC has previously identified as the average time taken for research findings to enter the clinic. 

More broadly, a substantial fraction of this proposal is dedicated to a detailed molecular investigation of intracellular parasitism by cryptococci. The information arising from this section impacts not only on cryptococcal disease, but also provides detailed information on intracellular parasitism and phagocyte biology that will be of value to immunologists, cell biologists and microbiologists. Specifically, non-lytic expulsion processes, similar to the one we propose to study, have now been identified in a diverse range of human pathogens. Hence both clinical and non-clinical colleagues working on other infections (and thus, ultimately, their patients) will benefit from the data we produce. 

Finally, the processes we propose to investigate are tightly linked to host cell vesicle trafficking and exocytosis. Thus we will be generating both data and reagents of value to a wide range of individuals, ranging from academic cell biologists to commercial microscope companies.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-04-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>380396</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Heitman laboratory, Duke, USA</gtr:description><gtr:id>B7D1FA20-9951-47BA-A73B-77B068A24E9E</gtr:id><gtr:impact>Resulted in preliminary data for a grant funded by the Wellcome Trust. Joint publication (PMID: 20421942)</gtr:impact><gtr:outcomeId>FBCC6EB0ABC-1</gtr:outcomeId><gtr:partnerContribution>Ongoing research collaboration</gtr:partnerContribution><gtr:piContribution>Research visit by Hansong Ma (PhD student) and subsequently myself to Duke University. Resulted in preliminary data for a grant, recently funded by the Wellcome Trust</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Tihana Bicanic</gtr:description><gtr:id>3AF61537-F100-41B8-9D68-4F2ACA0D7ECB</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>HCodTrZ4NPi-1</gtr:outcomeId><gtr:partnerContribution>Provision of clinical samples for analysis</gtr:partnerContribution><gtr:piContribution>Conducting in vitro cell testing of clinical fungal isolates</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>'Meet the Scientist' (University of Birmingham)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B5D7A7A1-E053-4DCC-917C-7544E2D6E496</gtr:id><gtr:impact>Approximately 300 children attended a 'Meet the Scientist' Biology Spring Series for Schoolchildren, in which I gave a talk about microbiology and science. This took place at my organisation, the School of Biosciences, University of Birmingham. This sparked questions and a discussion, and the schools involved reported increased interest amongst their pupils in the subject areas.</gtr:impact><gtr:outcomeId>56b1faf883e7d7.20364689</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Pop-Up Shop, Birmingham City Centre</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A900EB6B-93ED-4C97-B130-2DA9CFEF5D8F</gtr:id><gtr:impact>Open-door exhibition in Birmingham shopping centre. Around 100 children and adults dropped in during the day to learn more about current research in microbiology at Birmingham.

None at present; awaiting formal feedback</gtr:impact><gtr:outcomeId>542954e0801815.71115378</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Meet the Scientist' School Visit (Rugby)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4CFA1571-06BD-4F33-98AB-6C6532ECE789</gtr:id><gtr:impact>Gave a talk to approximately 100 school pupils at Ashlawn School Rugby re microbiology and science. This sparked questions and discussion afterwards, and the school reported an increased interest in related subject areas.</gtr:impact><gtr:outcomeId>56b1fc32596a49.89279319</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Meet the Scientist' School Visit (Derby)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>39294864-0BE2-4550-AEC0-1101461970AD</gtr:id><gtr:impact>I gave talk about microbiology and science to around 100 pupils at Chellaston Academy, Derby. This sparked questions and discussion afterwards, and the school reported an increased interest in related subject areas.</gtr:impact><gtr:outcomeId>56b1fb95958a81.29467884</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientifique at the Pure Bar, Birmingham City Centre</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>95CA5CB0-DAD7-40C9-B432-E5E728A8466F</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards.

I have been invited to talk to MENSA.</gtr:impact><gtr:outcomeId>5550cb23229b76.51322783</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cafescientifique.org/index.php?option=com_contentbuilder&amp;title=uk-birmingham&amp;controller=details&amp;id=1&amp;record_id=19&amp;Itemid=478&amp;limitstart=0&amp;filter_order=</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Life Under a Lens', UK Fungus Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0A390851-310D-4BC8-B358-5DEE277A0064</gtr:id><gtr:impact>Took part in an interactive activity day to promote UK Fungus Day at the Birmingham ThinkTank (science museum). Introduced nearly 300 children and their families to fungi-related activities together with my Lab (MayLab) and the wider Host Pathogen Interaction (HAPI) Lab.</gtr:impact><gtr:outcomeId>56b1ed2e345658.71240096</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.biosciences-labs.bham.ac.uk/may/Home.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Microbiology Lecture for Schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>48222880-4405-4544-B0B2-65C7C1BC1E50</gtr:id><gtr:impact>Gave a talk 'The Human Zoo', to 350 school children interested in studying Medicine, Biomedical or Biological Sciences at University at the Annual Microbiology Lecture for Schools at Aberdeen University. This sparked questions and discussion afterwards and increased interest in Microbiology from many of those who attended.</gtr:impact><gtr:outcomeId>56b1fe19c06cb8.67140164</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.abdn.ac.uk/events/8578/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>779C725E-44F5-4A6E-AE03-3E9016114B94</gtr:id><gtr:title>Custom-Made Quorum Sensing for a Eukaryote.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a26eb209c5f80427042dfc1afd2e2f5c"><gtr:id>a26eb209c5f80427042dfc1afd2e2f5c</gtr:id><gtr:otherNames>May RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>57a8632c949761.65243739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14E2EA24-50F3-40AD-844E-528443F36DEA</gtr:id><gtr:title>'Division of labour' in response to host oxidative burst drives a fatal Cryptococcus gattii outbreak.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c785f6eb306ac4299dab556c4c0a6633"><gtr:id>c785f6eb306ac4299dab556c4c0a6633</gtr:id><gtr:otherNames>Voelz K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>554cc555ccf7d5.89934153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF3828A8-ED17-48AF-8F6E-726B1093822F</gtr:id><gtr:title>Mechanisms of microbial escape from phagocyte killing.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b1f5fc01da53864652718aa884941e3"><gtr:id>0b1f5fc01da53864652718aa884941e3</gtr:id><gtr:otherNames>Smith LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_12905_25_23514140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF2C9070-F45B-4F92-A4DA-CDDEC347DFDE</gtr:id><gtr:title>The fungal pathogen Cryptococcus neoformans manipulates macrophage phagosome maturation.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b1f5fc01da53864652718aa884941e3"><gtr:id>0b1f5fc01da53864652718aa884941e3</gtr:id><gtr:otherNames>Smith LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>585d395503ffb7.21950041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9BBAF35-BFCA-44FB-85FD-3F6C01335CFB</gtr:id><gtr:title>Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997-2010.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b8900e6224e35a024d515ded10f432d"><gtr:id>5b8900e6224e35a024d515ded10f432d</gtr:id><gtr:otherNames>Head MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5555ed3c4a2927.69083425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66C9ED78-0BBA-42C2-ABF2-2713ED633052</gtr:id><gtr:title>Editorial overview: Host-microbe interactions: fungi.</gtr:title><gtr:parentPublicationTitle>Current opinion in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9e7670819526636d49a136b653addc7"><gtr:id>e9e7670819526636d49a136b653addc7</gtr:id><gtr:otherNames>Brown GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1369-5274</gtr:issn><gtr:outcomeId>5a7da254edc9a1.57436485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69D9B5CC-798A-444C-B478-0AAC6371C533</gtr:id><gtr:title>Species-specific antifungal activity of blue light.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/604018a4f7e3fc38567a47baac33904b"><gtr:id>604018a4f7e3fc38567a47baac33904b</gtr:id><gtr:otherNames>Trzaska WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a7da0e680b8e3.79554165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A416781-102B-4274-9772-E575AD0B45F1</gtr:id><gtr:title>Regulator of G-Protein Signalling-14 (RGS14) Regulates the Activation of aM?2 Integrin during Phagocytosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/742933148c0adb22faba533f06fa5cd1"><gtr:id>742933148c0adb22faba533f06fa5cd1</gtr:id><gtr:otherNames>Lim J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12905_25_23805333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>730519DD-7FB4-40A5-983C-F13036FE035B</gtr:id><gtr:title>Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5.</gtr:title><gtr:parentPublicationTitle>Science advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1add5726aa8eb0ec0fd864f867799cf3"><gtr:id>1add5726aa8eb0ec0fd864f867799cf3</gtr:id><gtr:otherNames>Gilbert AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2375-2548</gtr:issn><gtr:outcomeId>5a7da1c8d052b7.74901674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4AA06C1-FD67-4582-AE0B-AE67F0DC0B25</gtr:id><gtr:title>Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6dd8c9d9600f2ef429868b82ca5e1e50"><gtr:id>6dd8c9d9600f2ef429868b82ca5e1e50</gtr:id><gtr:otherNames>Johnston SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_12905_25_23127124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3B34477-9BAB-4410-8FCD-39D210C80371</gtr:id><gtr:title>New weapons in the Cryptococcus infection toolkit.</gtr:title><gtr:parentPublicationTitle>Current opinion in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e153f908b9f57185e30188ad78c02008"><gtr:id>e153f908b9f57185e30188ad78c02008</gtr:id><gtr:otherNames>Taylor-Smith LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1369-5274</gtr:issn><gtr:outcomeId>58c9340b406684.05248267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F9E0336-57EA-4B9B-9E07-D1BB4CF32116</gtr:id><gtr:title>Cryptococcal phospholipase B1 is required for intracellular proliferation and control of titan cell morphology during macrophage infection.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/583610675221e4e3376e5c12050eb287"><gtr:id>583610675221e4e3376e5c12050eb287</gtr:id><gtr:otherNames>Evans RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>554cb921c1c162.93698375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C44D2A86-8D1E-496F-8E74-24F958C42059</gtr:id><gtr:title>Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages.</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0e2046b76a55717f5f6daad31548206"><gtr:id>d0e2046b76a55717f5f6daad31548206</gtr:id><gtr:otherNames>Samantaray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>57a8611f3a65e2.99158648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3638D12F-C417-4D7D-9549-31D2115593C4</gtr:id><gtr:title>Cryptococcus: from environmental saprophyte to global pathogen.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a26eb209c5f80427042dfc1afd2e2f5c"><gtr:id>a26eb209c5f80427042dfc1afd2e2f5c</gtr:id><gtr:otherNames>May RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>57a86625185608.24367835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EE71731-F9F6-456D-86F0-71D76A427AE7</gtr:id><gtr:title>Cryptococcus neoformans Intracellular Proliferation and Capsule Size Determines Early Macrophage Control of Infection.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4b5163ebef084d513c4fac4c8eb802"><gtr:id>6c4b5163ebef084d513c4fac4c8eb802</gtr:id><gtr:otherNames>Bojarczuk A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>57a8638f323930.08370645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FBAF1EB-0B8D-471E-AE2E-B43CEB77BF69</gtr:id><gtr:title>Microevolutionary traits and comparative population genomics of the emerging pathogenic fungus Cryptococcus gattii.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adf5d27803697e770cac47374260e978"><gtr:id>adf5d27803697e770cac47374260e978</gtr:id><gtr:otherNames>Farrer RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>58c9334fc40ea8.62821098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AC4D33E-3D3F-4F84-A2AE-50FA4EC34F2C</gtr:id><gtr:title>The Case for Adopting the &amp;quot;Species Complex&amp;quot; Nomenclature for the Etiologic Agents of Cryptococcosis.</gtr:title><gtr:parentPublicationTitle>mSphere</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4d846ceffc457212d56ea33c30a096c"><gtr:id>d4d846ceffc457212d56ea33c30a096c</gtr:id><gtr:otherNames>Kwon-Chung KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-5042</gtr:issn><gtr:outcomeId>58c9335047c7b7.32918601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C24700-B082-45E1-9164-EAD3826A9C5A</gtr:id><gtr:title>Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b509571ce35681e0c2b4e609b747c728"><gtr:id>b509571ce35681e0c2b4e609b747c728</gtr:id><gtr:otherNames>Sabiiti W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_540e193e193707f7d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C968D5-171A-449C-8242-543C38639327</gtr:id><gtr:title>Top-Down LESA Mass Spectrometry Protein Analysis of Gram-Positive and Gram-Negative Bacteria.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society for Mass Spectrometry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3302eec0f557262848decda407dbd573"><gtr:id>3302eec0f557262848decda407dbd573</gtr:id><gtr:otherNames>Kocurek KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-0305</gtr:issn><gtr:outcomeId>5a7da1445cdc15.24789306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EC8BA0E-1BA2-49B1-B8A7-227E35FB281A</gtr:id><gtr:title>Using Flow Cytometry to Analyze Cryptococcus Infection of Macrophages.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/583610675221e4e3376e5c12050eb287"><gtr:id>583610675221e4e3376e5c12050eb287</gtr:id><gtr:otherNames>Evans RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:isbn>978-1-4939-6579-3</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58c9335013c8b1.88574956</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J008176/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>